Divi's Laboratories Ltd's shares were trading nearly 3% lower on December 5 as Novartis failed to persuade a US appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
A treatment shown in initial studies to dramatically reduce death could become a "game-changer" in the treatment of liver disease ...
Short selling involves borrowing shares and then selling them at current market prices. In the successful version of the ...
In my talks on innovation and simplification, I pose a simple question to my audiences: "How many of you wish you had more ...
Novartis failed to persuade a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
This summary covers recent significant events in the health sector, including major deals, court decisions, new drug ...
The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...
Green roofs are celebrated for their environmental and financial benefits. Commonplace in Germany, they are slowly growing on ...
Monte Rosa Therapeutics stock surged after a recent partnership with Novartis, despite limited clinical results. Can the ...
Oppenheimer analysts, led by Jay Olson, said the data support development in earlier-line settings, "and its three-month performance strengthens our optimism surrounding longer-term MMR data," which ...
The U.S. Court of Appeals has reportedly ruled against Novartis (NVS) in its bid to prevent the U.S. launch of a generic ...
European markets rose to a one-month peak despite political uncertainty in France, where a no-confidence vote threatens Prime ...